At Lundbeck, we are tirelessly dedicated to restoring brain health so every person can be their best. Lundbeck is the only global biopharmaceutical company focused solely on brain diseases. Our legacy in neuroscience goes back seven decades and we have a long heritage of innovation. Lundbeck has developed and commercialized some of the world’s most widely prescribed therapies for psychiatric and neurological disorders. Today, we remain uncompromisingly committed to improving the quality of life for people impacted by brain disorders. Lundbeck is unique from other biopharmaceutical companies in that we are 70 percent owned by a research-focused foundation. We have a deep and productive pipeline, and continue to bring forward symptomatic therapies to help people live better lives, while simultaneously pursuing disease-modifying treatments.
Lundbeck is proud to be an equal opportunity workplace and is an affirmative action employer. We are committed to equal employment opportunity regardless of race, color, religion, sex, sexual orientation, gender identity, age, national origin, disability, protected veteran status, and any other characteristic protected by law, rule, or regulation.
For more than 70 years, Lundbeck has been at the forefront of neuroscience research. We are committed to developing and providing innovative therapies that improve the quality of life for people affected by psychiatric and neurological disorders. When we assess a medical condition, we see the person behind the disease, and we have deep connections with the communities we serve. In the United States, our 900+ employees stand shoulder-to-shoulder with patients, families and caregivers impacted by brain disorders.